Skip to main
SNTI
SNTI logo

SNTI Stock Forecast & Price Target

SNTI Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 75%
Buy 0%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Senti Biosciences has demonstrated a promising outlook, particularly highlighted by initial data from the Phase I trial of SENTI-202, where two out of three patients achieved MRD-negative complete remissions in relapsed/refractory hematologic malignancies, suggesting a strong potential for efficacy in treating challenging conditions like AML. The company's innovative approach using allogeneic CAR-NK cells, combined with its unique gene circuit technologies, positions it favorably in an oncology landscape characterized by significant unmet needs and competitive therapy profiles. Additionally, Senti's strategic investment in establishing in-house GMP manufacturing capabilities underscores its commitment to scaling production efficiently, supporting future growth and operational sustainability.

Bears say

The financial outlook for Senti Biosciences Inc. appears negative due to the potential for downward revisions in the company's price target based on risk-adjusted projections. The repeated emphasis on the potential for these revisions suggests significant concerns regarding the company's current valuation and future performance. Furthermore, the ongoing uncertainties may undermine investor confidence in the profitability and viability of Senti Biosciences's product candidates, particularly in the competitive field of biotechnology.

SNTI has been analyzed by 4 analysts, with a consensus rating of Buy. 75% of analysts recommend a Strong Buy, 0% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Senti Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Senti Biosciences Inc (SNTI) Forecast

Analysts have given SNTI a Buy based on their latest research and market trends.

According to 4 analysts, SNTI has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Senti Biosciences Inc (SNTI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.